ID: ALA373855

Max Phase: Preclinical

Molecular Formula: C10H14N2O5S

Molecular Weight: 274.30

Molecule Type: Small molecule

Representations

Canonical SMILES:  CSc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C10H14N2O5S/c1-18-7-3-12(10(16)11-9(7)15)8-2-5(14)6(4-13)17-8/h3,5-6,8,13-14H,2,4H2,1H3,(H,11,15,16)/t5-,6+,8+/m0/s1

Standard InChI Key:  NQJYWLBQAUXGGI-SHYZEUOFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 274.30

Molecular Weight (Monoisotopic): 274.0623

AlogP: -1.10

#Rotatable Bonds: 3

Polar Surface Area: 104.55

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.48

CX Basic pKa:

CX LogP: -0.86

CX LogD: -0.86

Aromatic Rings: 1

Heavy Atoms: 18

QED Weighted: 0.60

Np Likeness Score: 0.71

References

1. Hampton A, Chawla RR, Kappler F..  (1982)  Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.,  25  (6): [PMID:7097717] [10.1021/jm00348a007]

2. Helguera AM, Rodríguez-Borges JE, García-Mera X, Fernández F, Cordeiro MN..  (2007)  Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.,  50  (7): [PMID:17341060] [10.1021/jm061445m]

Source

Source(1):

• Scientific Literature